15.30 0.00 (0.00%)
After hours: 4:41PM EDT
|Bid||15.09 x 1200|
|Ask||15.95 x 900|
|Day's range||14.93 - 15.82|
|52-week range||9.01 - 29.90|
|PE ratio (TTM)||N/A|
|Earnings date||7 Mar 2018 - 12 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.67|
Collegium Pharmaceutical, Inc. (COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas. Poster #39, presented by Dr. Janetta Iwanicki, Scientific Director of Research and Surveillance at Rocky Mountain Poison & Drug Center – Denver Health and Hospital Authority, is titled "Assessment of Tapentadol API Abuse Liability with the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System Poison Center Program". It compares the rate of intentional abuse of tapentadol active pharmaceutical ingredient (API) to other opioids in the RADARS System Poison Center Program.
Collegium Pharmaceutical’s net loss decreased from $21.12 million in the second quarter of 2017 to $13.06 million in the second quarter of 2018, which translated into a net loss per share of $0.40 in the second quarter as compared with a net loss per share of $0.72 in the second quarter of 2017. In August 2018, of the total eight analysts covering Collegium Pharmaceutical, three analysts have given the stock a “strong buy” rating, and five analysts have given Collegium Pharmaceutical a “buy” rating. The mean rating for Collegium Pharmaceutical stock is 1.63 with a target price of $31.67.
Collegium Pharmaceutical (COLL) is a specialty pharmaceutical company focused on bringing to market products for people suffering from pain. In January 2018, Collegium began commercializing Nucynta products. Collegium Pharmaceutical generated total revenues of $73.06 million in the second quarter of 2018 as compared with $3.56 million in the second quarter of 2017.
The US government is taking steps to address the opioid epidemic and rapidly rising addiction levels in the country. On August 16, President Trump asked the Attorney General to start filing federal lawsuits against certain companies that supply opioids to hospitals. In this series, we’ll analyze the financial performance, products, analysts’ views, valuation metrics, and the stock performance of Insys Therapeutics (INSY), Cara Therapeutics (CARA), Collegium Pharmaceutical (COLL), and Pacira Pharmaceuticals (PCRX).
NEW YORK, Aug. 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fiesta ...
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 65.91% and 4.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018 Xtampza ER prescriptions grew by 23% in the second quarter of 2018 Cash balance ...
CANTON, Mass., July 20, 2018-- Collegium Pharmaceutical, Inc. announced today that the Company will host a conference call and live audio webcast on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time. ...
CANTON, Mass., July 10, 2018-- Collegium Pharmaceutical, Inc. today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, ...
While small-cap stocks, such as Collegium Pharmaceutical Inc (NASDAQ:COLL) with its market cap of US$879.63m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 57 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 54 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...